HCM
HealthcareHUTCHMED (China) Limited
$13.37
$-0.28 (-2.05%)
Jan 5, 2026
Price History (1Y)
Analysis
HUTCHMED (China) Limited is a healthcare company operating in the drug manufacturers - specialty & generic industry. It has a market capitalization of $2.41 billion and generates revenue of approximately $602.20 million on a trailing 12-month basis. The company employs 1,780 individuals. The company's financial health indicates significant profitability, with a profit margin of 77.5%. However, it also reports negative operating and EBITDA margins. HUTCHMED's balance sheet shows substantial cash reserves of $1.37 billion, which is more than its debt of $100.73 million. The company's return on equity (ROE) stands at 46.9%, while its return on assets (ROA) is -0.8%. The debt-to-equity ratio is 8.11. HUTCHMED's valuation multiples include a price-to-earnings (P/E) ratio of 5.16 on a trailing basis and 29.05 on a forward basis. The company reports a revenue growth rate of -9.2% year-over-year, while its earnings growth is 1633.3%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Visit website →Key Statistics
- Market Cap
- $2.41B
- P/E Ratio
- 5.16
- 52-Week High
- $19.50
- 52-Week Low
- $11.51
- Avg Volume
- 31.33K
- Beta
- 0.50
Company Info
- Exchange
- NMS
- Country
- Hong Kong
- Employees
- 1,780